Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Molecular Pharmacology
  4. Volume 17, Issue 1
  5. Article
Volume 17, Issue 1
  • ISSN: 1874-4672
  • E-ISSN: 1874-4702
file format pdf download PDF
side by side viewer icon HTML

Abstract

Thyroid cancer is one of the most common endocrine neoplasms. Treatment methods include surgical resection, radioactive iodine therapy, inhibition of thyroid-stimulating hormone, and inhibition of kinase-based target therapies. These treatments induced adverse effects. possesses antioxidant, anticancer, burn-healing, and anti-inflammatory activities, and Shikonin is the main ingredient. Antithyroid cancer studies of Shikonin discovered that it inhibited thyroid cancer cell migration and invasion by suppressing the epithelial-mesenchymal transition; induced cell cycle arrest; induced DNA damage and apoptosis by producing excessive reactive oxygen species; upregulated Bax; increased the stability of p53; decreased the expression of Mdm2; downregulated Slug and MMP-2, MMP-9, and MMP-14; repressed the phosphorylation of Erk and Akt; activated the p16/retinoblastoma protein pathway, leading to apoptosis; suppressed the expression of DNMT1; reduced the PTEN gene methylation; increased the expression of PTEN, leading to the inhibition of migration; increased LC3-II to induce autophagy and apoptosis of medullary thyroid carcinoma; and upregulated βII-tubulin in the cell to produce less resistance to cisplatin and paclitaxel, without cross-resistance to other anticancer agents. studies showed that it is safe in Sprague-Dawley rats, Beagle dogs, and nude mice.

© 2024 The Author(s). Published by Bentham Science Publisher.
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Loading

Article metrics loading...

/content/journals/cmp/10.2174/1874467217666230904104414
2023-10-13
2024-11-22

  • From This Site

    /content/journals/cmp/10.2174/1874467217666230904104414
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/cmp/17/1/CMP-17-E040923220678.html?itemId=/content/journals/cmp/10.2174/1874467217666230904104414&mimeType=html&fmt=ahah

References

  1. WiltshireJ. J. DrakeT. M. UttleyL. BalasubramanianS. P. Systematic Review of Trends in the Incidence Rates of Thyroid Cancer.Thyroid.2016261115411552
     [Google Scholar]
  2. BonjocK.J. YoungH. WarnerS. GernonT. MaghamiE. ChaudhryA. Thyroid cancer diagnosis in the era of precision imaging.J. Thorac. Dis.20201295128513910.21037/jtd.2019.08.3733145090
     [Google Scholar]
  3. Haroon Al RasheedM.R. XuB. Molecular Alterations in Thyroid Carcinoma.Surg. Pathol. Clin.201912492193010.1016/j.path.2019.08.00231672298
     [Google Scholar]
  4. HaugenB. R. AlexanderE. K. BibleK. C. DohertyG. M. MandelS. J. NikiforovY. E. PaciniF. RandolphG. W. SawkaA. M. SchlumbergerM. SchuffK. G. ShermanS. I. SosaJ. A. StewardD. L. TuttleR. M. WartofskyL. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.Thyroid20162611133
     [Google Scholar]
  5. KimB.H. KimI.J. Recent Updates on the Management of Medullary Thyroid Carcinoma.Endocrinol. Metab. (Seoul)201631339239910.3803/EnM.2016.31.3.39227586449
     [Google Scholar]
  6. CabanillasM.E. RyderM. JimenezC. Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond.Endocr. Rev.20194061573160410.1210/er.2019‑0000731322645
     [Google Scholar]
  7. KarimiA. MajlesiM. Rafieian-KopaeiM. Herbal versus synthetic drugs; beliefs and facts.J. Nephropharmacol.201541273028197471
     [Google Scholar]
  8. CooperD.S. Antithyroid Drugs.N. Engl. J. Med.2005352990591710.1056/NEJMra04297215745981
     [Google Scholar]
  9. Fard-EsfahaniA. Emami-ArdekaniA. FallahiB. Fard-EsfahaniP. BeikiD. Hassanzadeh-RadA. EftekhariM. Adverse effects of radioactive iodine-131 treatment for differentiated thyroid carcinoma.Nucl. Med. Commun.201435880881710.1097/MNM.000000000000013224751702
     [Google Scholar]
  10. WirthL.J. ShermanE. RobinsonB. SolomonB. KangH. LorchJ. WordenF. BroseM. PatelJ. LeboulleuxS. GodbertY. BarlesiF. MorrisJ.C. OwonikokoT.K. TanD.S.W. GautschiO. WeissJ. de la FouchardièreC. BurkardM.E. LaskinJ. TaylorM.H. KroissM. MedioniJ. GoldmanJ.W. BauerT.M. LevyB. ZhuV.W. LakhaniN. MorenoV. EbataK. NguyenM. HeirichD. ZhuE.Y. HuangX. YangL. KheraniJ. RothenbergS.M. DrilonA. SubbiahV. ShahM.H. CabanillasM.E. Efficacy of selpercatinib in RET -altered thyroid cancers.N. Engl. J. Med.2020383982583510.1056/NEJMoa200565132846061
     [Google Scholar]
  11. SchlumbergerM. TaharaM. WirthL.J. RobinsonB. BroseM.S. EliseiR. HabraM.A. NewboldK. ShahM.H. HoffA.O. GianoukakisA.G. KiyotaN. TaylorM.H. KimS.B. KrzyzanowskaM.K. DutcusC.E. de las HerasB. ZhuJ. ShermanS.I. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.N. Engl. J. Med.2015372762163010.1056/NEJMoa140647025671254
     [Google Scholar]
  12. EliseiR. SchlumbergerM.J. MüllerS.P. SchöffskiP. BroseM.S. ShahM.H. LicitraL. JarzabB. MedvedevV. KreisslM.C. NiederleB. CohenE.E.W. WirthL.J. AliH. HesselC. YaronY. BallD. NelkinB. ShermanS.I. Cabozantinib in progressive medullary thyroid cancer.J. Clin. Oncol.201331293639364610.1200/JCO.2012.48.465924002501
     [Google Scholar]
  13. ResteghiniC. CavalieriS. GalbiatiD. GranataR. AlfieriS. BergaminiC. BossiP. LicitraL. LocatiL.D. Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients.Best Pract. Res. Clin. Endocrinol. Metab.201731334936110.1016/j.beem.2017.04.01228911730
     [Google Scholar]
  14. LeboulleuxS. BastholtL. KrauseT. de la FouchardiereC. TennvallJ. AwadaA. GómezJ.M. BonichonF. LeenhardtL. SouffletC. LicourM. SchlumbergerM.J. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: A randomised, double-blind, phase 2 trial.Lancet Oncol.201213989790510.1016/S1470‑2045(12)70335‑222898678
     [Google Scholar]
  15. JinY. XuZ. YanH. HeQ. YangX. LuoP. A Comprehensive Review of Clinical Cardiotoxicity Incidence of FDA-Approved Small-Molecule Kinase Inhibitors.Front. Pharmacol.20201189110.3389/fphar.2020.0089132595510
     [Google Scholar]
  16. DyG.K. AdjeiA.A. Understanding, recognizing, and managing toxicities of targeted anticancer therapies.CA Cancer J. Clin.201363424927910.3322/caac.2118423716430
     [Google Scholar]
  17. CellaD. LaiJ. ChangC.H. PetermanA. SlavinM. Fatigue in cancer patients compared with fatigue in the general United States population.Cancer200294252853810.1002/cncr.1024511900238
     [Google Scholar]
  18. FarhoodB. MortezaeeK. GoradelN.H. KhanlarkhaniN. SalehiE. NashtaeiM.S. NajafiM. SahebkarA. Curcumin as an anti-inflammatory agent: Implications to radiotherapy and chemotherapy.J. Cell. Physiol.201923455728574010.1002/jcp.2744230317564
     [Google Scholar]
  19. MitchellS.A. Cancer-related fatigue: State of the science.PM R20102536438310.1016/j.pmrj.2010.03.02420656618
     [Google Scholar]
  20. BowerJ.E. The role of neuro-immune interactions in cancer-related fatigue: Biobehavioral risk factors and mechanisms.Cancer2019125335336410.1002/cncr.3179030602059
     [Google Scholar]
  21. EsmailA. Chemical Constituents and Pharmacological Effects of Lithospermum.J Pharm2019981221
     [Google Scholar]
  22. ChoiS.B. BaeG.S. JoI.J. ParkK-C. SeoS-H. KimD-G. ShinJ-Y. GwakT-S. LeeJ-H. LeeG-S. ParkS-J. SongH-J. The anti-inflammatory effect of Lithospermum Erythrorhizon on lipopolysaccharide - induced inflammatory response in RAW 264.7 cells.Korea J Herbol2013282677310.6116/kjh.2013.28.2.67
     [Google Scholar]
  23. AndújarI. RíosJ. GinerR. RecioM. Pharmacological properties of shikonin - a review of literature since 2002.Planta Med.201379181685169710.1055/s‑0033‑135093424155261
     [Google Scholar]
  24. ChenL. KeC. JingY. Anti-inflammatory mechanism research of Radix Arnebiae and its preparations.World Chinese Medicine.201813613631367
     [Google Scholar]
  25. WagnerH. WittmannD. SchäferW. Zur chemischen struktur der lithospermsäure aus lithospermum officinale L.Tetrahedron Lett.197516854755010.1016/S0040‑4039(00)71917‑4
     [Google Scholar]
  26. HaghbeenK. MozaffarianV. GhaffariF. PourazeeziE. SarajiM. JoupariM.D. Lithospermum officinale callus produces shikalkin.Biologia (Bratisl.)200661446346710.2478/s11756‑006‑0077‑x
     [Google Scholar]
  27. WagnerH. KoenigH. Isolation of a 6,9,12,15n-octadecatetraenoic acid from the fruits of Lithospermum officinale L.Biochem. Z.1963339321221814206230
     [Google Scholar]
  28. ZhaoX. WangG. FeiH. Study on the extraction and anti-inflammatory effect of the active components of Lithospermum officinale.Pharmacol. Clin. Chinese Trad. Herb.20082443638
     [Google Scholar]
  29. FengGe WangXiao-dong WangYu-chun Advances in studies on medicinal Radix Arnebiae Seu Lithospermi.Chinese Trad Herb Drugs200334969
     [Google Scholar]
  30. MinC. JunT. LiS. Recent advances in the research on pharmacological actions and quantitative analyses of naphthoquinones in Chinese medicinal herb “Zicao”.Yao Xue Xue Bao2018531220262039
     [Google Scholar]
  31. ZhangY. SunB. HuangZ. ZhaoD.W. ZengQ. Shikonin inhibites migration and invasion of thyroid cancer cells by downregulating DNMT1.Med. Sci. Monit.20182466167010.12659/MSM.90838129389913
     [Google Scholar]
  32. YangQ. JiM. GuanH. ShiB. HouP. Shikonin inhibits thyroid cancer cell growth and invasiveness through targeting major signaling pathways.J. Clin. Endocrinol. Metab.20139812E1909E191710.1210/jc.2013‑258324106286
     [Google Scholar]
  33. GuM. LiX. TangX. Effect of autophagy on the shikonin induced apoptosis of human medullary thyroid carcinoma TT cells.Int. J. Clin. Exp. Med.2016991742817434
     [Google Scholar]
  34. TangX. ZhangC. WeiJ. FangY. ZhaoR. YuJ. Apoptosis is induced by shikonin through the mitochondrial signaling pathway.Mol. Med. Rep.20161343668367410.3892/mmr.2016.496726935754
     [Google Scholar]
  35. WuH. XieJ. PanQ. WangB. HuD. HuX. Anticancer agent shikonin is an incompetent inducer of cancer drug resistance.PLoS One201381e5270610.1371/journal.pone.005270623300986
     [Google Scholar]
  36. HanC.T. KimM.J. MoonS.H. JeonY.R. HwangJ.S. NamC. ParkC.W. LeeS.H. NaJ.B. ParkC.S. ParkH.W. LeeJ.M. JangH.S. ParkS.H. HanK.G. ChoiY.W. LeeH.Y. KangJ.K. Acute and 28-day subacute toxicity studies of hexane extracts of the roots of lithospermum erythrorhizon in sprague-dawley rats.Toxicol. Res.201531440341410.5487/TR.2015.31.4.40326877842
     [Google Scholar]
  37. NamC. HwangJ.S. KimM.J. ChoiY.W. HanK.G. KangJ.K. Single- and repeat-dose oral toxicity studies of lithospermum erythrorhizon extract in dogs.Toxicol. Res.2015311778810.5487/TR.2015.31.1.07725874036
     [Google Scholar]
/content/journals/cmp/10.2174/1874467217666230904104414
Loading
Research Progress of the Molecular Mechanism of Antithyroid Cancer Activity of Shikonin
Curr Mol Pharmacol 17, e040923220678 (2024); https://doi.org/10.2174/1874467217666230904104414
/content/journals/cmp/10.2174/1874467217666230904104414
/content/journals/cmp/10.2174/1874467217666230904104414
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): apoptosis; Autophagy; Drug resistance; Lithospermum officinale; Shikonin; Thyroid cancer; Toxicological study

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test